Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2017 Filed Dec 13, 2017 22:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 5,215 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-065483 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,215 shares Expires 2018-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 12,206 | $13.52 | $164,972.63 |
DisclosureSEC source: 0001209191-17-065483 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.63. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 12,206 | $13.52 | $164,972.63 |
DisclosureSEC source: 0001209191-17-065483 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.63. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 47,213 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-064235 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,787 Underlying: Common Stock · 47,213 shares Expires 2018-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 47,213 | $13.61 | $642,734.18 |
DisclosureSEC source: 0001209191-17-064235 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.92. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 47,213 | $13.61 | $642,734.18 |
DisclosureSEC source: 0001209191-17-064235 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.92. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 19,013 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 19,013 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 19,013 | $14.76 | $280,544.42 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 19,013 | $14.76 | $280,544.42 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 19,013 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 19,013 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 19,013 | $14.75 | $280,447.45 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 19,013 | $14.75 | $280,447.45 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 52,722 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,521 Underlying: Common Stock · 52,722 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 52,722 | $14.75 | $777,649.50 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 01:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 52,722 | $14.75 | $777,649.50 |
DisclosureSEC source: 0001209191-17-057532 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 52,722 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,521 Underlying: Common Stock · 52,722 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 52,722 | $14.75 | $777,649.50 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 17, 2017 Filed Oct 20, 2017 21:13 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 52,722 | $14.75 | $777,649.50 |
DisclosureSEC source: 0001209191-17-057662 · doc4a.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 47,135 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 14 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,243 Underlying: Common Stock · 47,135 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 47,135 | $14.75 | $695,241.25 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 47,135 | $14.75 | $695,241.25 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 47,135 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 14 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,243 Underlying: Common Stock · 47,135 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 47,135 | $14.75 | $695,241.25 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 16, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 47,135 | $14.75 | $695,241.25 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,160 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 13 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,378 Underlying: Common Stock · 22,160 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,160 | $14.75 | $326,866.65 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F5 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,160 | $14.75 | $326,866.65 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 13, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,160 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 13 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,378 Underlying: Common Stock · 22,160 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 13, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,160 | $14.75 | $326,866.65 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F5 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 13, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,160 | $14.75 | $326,866.65 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 192,133 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 12 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,972 Underlying: Common Stock · 192,133 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 165,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 11 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2023-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 3,462 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 10 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,538 Underlying: Common Stock · 3,462 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 13,622 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 9 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,378 Underlying: Common Stock · 13,622 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 5,783 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · derivative · entry 8 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,024 Underlying: Common Stock · 5,783 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 380,000 | $14.25 | $5,414,810.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 12, 2017 Filed Oct 17, 2017 01:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 380,000 | $14.25 | $5,414,810.00 |
DisclosureSEC source: 0001209191-17-057052 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 192,133 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 12 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,972 Underlying: Common Stock · 192,133 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 165,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 11 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2023-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 3,462 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 10 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,538 Underlying: Common Stock · 3,462 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 13,622 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 9 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,378 Underlying: Common Stock · 13,622 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 5,783 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · derivative · entry 8 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,024 Underlying: Common Stock · 5,783 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 380,000 | $14.25 | $5,414,810.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 12, 2017 Filed Oct 20, 2017 21:12 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 380,000 | $14.25 | $5,414,810.00 |
DisclosureSEC source: 0001209191-17-057661 · doc4a.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 26, 2017 Filed Sep 29, 2017 00:32 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 1,395 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-17-054346 · doc4a.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,105 Underlying: Common Stock · 1,395 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 29, 2017 00:32 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 1,395 | $14.36 | $20,032.20 |
DisclosureSEC source: 0001209191-17-054346 · doc4a.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | ConversionStock Options (right to buy) · Derivative | 1,395 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-17-054343 · doc4.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,105 Underlying: Common Stock · 1,395 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,395 | $14.36 | $20,032.20 |
DisclosureSEC source: 0001209191-17-054343 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 5,005 | $8.79 | $43,993.95 |
DisclosureSEC source: 0001209191-17-040798 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,606 Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 282,485 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-17-002450 · doc4.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,485 Underlying: Common Stock · 282,485 shares Expires 2027-01-03 F1 · derivative.exercise_date: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.